View Older Stories View More Recent Stories

Aug 28, 2024 07:30AM Palatin Technologies (PTN) Reports FDA Confirmed Acceptability of Remaining Phase 3 Trials for PL9643
Aug 28, 2024 07:30AM FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
Aug 22, 2024 07:30AM Palatin Technologies (PTN): First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Aug 22, 2024 07:30AM First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Jun 21, 2024 08:00AM Palatin Technologies (PTN) Receives $6.1M from Exercise of Warrants
Jun 21, 2024 08:00AM Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Jun 20, 2024 07:30AM Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Jun 12, 2024 07:30AM Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
May 15, 2024 07:30AM Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
May 9, 2024 07:30AM Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
May 2, 2024 07:30AM Palatin Technologies (PTN) Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
May 2, 2024 07:30AM Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Apr 30, 2024 07:30AM Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Apr 8, 2024 07:35AM Palatin Technologies (PTN) Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease Clinical Data Results Presented at ASCRS
Apr 8, 2024 07:30AM Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Feb 28, 2024 07:30AM Palatin Technologies (PTN) Reports Results of PL9643 MELODY-1 Phase 3 Trial
Feb 28, 2024 07:30AM Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Feb 15, 2024 07:30AM Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Feb 9, 2024 07:30AM Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Feb 5, 2024 07:30AM Palatin Technologies (PTN) Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease
Feb 5, 2024 07:30AM Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Feb 1, 2024 04:00PM Palatin Announces Closing of $10 Million Registered Direct Offering
Jan 30, 2024 08:01AM Palatin Technologies (PTN) Announces 1.83M Share Offering at $5.46/sh
Jan 30, 2024 08:00AM Palatin Announces $10 Million Registered Direct Offering
Jan 8, 2024 10:35AM Palatin Technologies (PTN) Provides Corporate Update, Highlights Strategic Priorities for 2024
Jan 8, 2024 10:33AM Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Dec 20, 2023 07:30AM Palatin Technologies (PTN) Completes Sale of Vyleesi
Dec 20, 2023 07:30AM Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Dec 18, 2023 04:15PM Palatin Technologies (PTN) Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Dec 18, 2023 04:15PM Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Nov 14, 2023 07:30AM Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Nov 9, 2023 07:30AM Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Oct 24, 2023 04:50PM Palatin Announces Closing of $5 Million Registered Direct Offering
Oct 23, 2023 07:31AM Palatin Technologies (PTN) Prices 2.36M Share Offering at $2.12/sh
Oct 23, 2023 07:30AM Palatin Announces $5 Million Registered Direct Offering
Oct 19, 2023 07:30AM Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Oct 18, 2023 07:42AM Palatin Technologies (PTN) Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Oct 18, 2023 07:30AM Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Oct 16, 2023 07:34AM Palatin (PTN) Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Oct 16, 2023 07:30AM Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Oct 13, 2023 04:15PM Palatin Technologies (PTN) Receives NYSE Non-compliance Notice
Oct 13, 2023 04:15PM Palatin Receives Notice of Non-Compliance from NYSE American
Sep 28, 2023 07:30AM Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
Sep 22, 2023 04:00PM Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
Sep 7, 2023 04:00PM Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 7, 2023 07:31AM Palatin Technologies (PTN) enrollment in PL9643 MELODY-1 Phase 3 study completed
Sep 7, 2023 07:30AM Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Aug 10, 2023 07:31AM Palatin Technologies (PTN) Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i
Aug 10, 2023 07:30AM Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
Aug 8, 2023 07:30AM Palatin's (PTN) Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China
View More Recent Stories View Older Stories